Featured
-
-
Article |
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
The anti-leprosy drug clofazimine inhibits coronavirus replication in several cell models and shows potent antiviral activity against SARS-CoV-2 infection in a hamster model, particularly when used in combination with remdesivir.
- Shuofeng Yuan
- , Xin Yin
- & Kwok-Yung Yuen
-
Article |
A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
A model in mouse using a species-adapted virus recapitulates features of SARS-CoV-2 infection and age-related disease pathogenesis in humans, and provides a model system for rapid evaluation of medical countermeasures against coronavirus disease 2019 (COVID-19).
- Kenneth H. Dinnon III
- , Sarah R. Leist
- & Ralph S. Baric
-
Article |
Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike
A diverse collection of potent neutralizing antibodies against the SARS-CoV-2 spike protein have been isolated from five patients with severe COVID-19 and high serum neutralization titres.
- Lihong Liu
- , Pengfei Wang
- & David D. Ho
-
Article |
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
The nucleotide analogue prodrug remdesivir reduces viral load and lung disease in a rhesus macaque model of SARS-CoV-2 infection.
- Brandi N. Williamson
- , Friederike Feldmann
- & Emmie de Wit
-
Letter |
Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430
A broad-spectrum antiviral small molecule is reported to act as an inhibitor of viral polymerase activity and is shown to be effective in protecting non-human primates from lethal filovirus infection when administered after exposure.
- Travis K. Warren
- , Jay Wells
- & Sina Bavari
-
News & Views |
How to escape treatment
Even during effective treatment with antiretroviral drugs, low levels of HIV persist. In part, this could be due to cell-to-cell transfer of multiple virions and the drugs' inability to inhibit replication when virus levels are high. See Letter p.95
- Steven G. Deeks
-
News |
New drug targets raise hopes for hepatitis C cure
As the first targeted therapies edge towards regulatory approval, attention turns to the next drugs in line.
- Heidi Ledford
-
Letter |
A diverse range of gene products are effectors of the type I interferon antiviral response
- John W. Schoggins
- , Sam J. Wilson
- & Charles M. Rice
-
Outlook |
Developing solutions
There is more to combating HIV in the developing world than providing affordable drugs. T. V. Padma looks at the innovative new strategies being employed.
- T. V. Padma
A condensate-hardening drug blocks RSV replication in vivo